Key result
Circumferential pulmonary vein ablation significantly improved atrial tachyarrhythmia recurrence-free survival compared with antiarrhythmic drug therapy (75.7% vs 18.8%; RR 3.73, 95% CI 2.47-5.63).
Why the study?
Does circumferential pulmonary vein ablation improve atrial tachyarrhythmia recurrence-free survival compared to antiarrhythmic drug therapy in patients with atrial fibrillation?
Population
432 patients with atrial fibrillation from 4 randomized controlled trials
Comparison
Circumferential pulmonary vein ablation (CPVA) vs Antiarrhythmic drug therapy (ADT)
Design
Meta-analysis
Authors
Loading...
Supports ablation over drugs for rhythm control in AF; confirms RCT superiority via Level 1 synthesis.
Systematic Review (n=432)
Does circumferential pulmonary vein ablation improve atrial tachyarrhythmia recurrence-free survival compared to antiarrhythmic drug therapy in patients with atrial fibrillation?
Effect estimate: RR 3.73 (95% CI 2.47-5.63)
Absolute Event Rate: 75.7% vs 18.8%
Circumferential pulmonary vein ablation significantly improves atrial tachyarrhythmia recurrence-free survival and reduces adverse events compared to antiarrhythmic drug therapy in patients with atrial fibrillation.
Amit Noheria (2008) conducted a systematic review in Atrial fibrillation (n=432). Circumferential pulmonary vein ablation (CPVA) vs. Antiarrhythmic drug therapy (ADT) was evaluated on Atrial tachyarrhythmia recurrence-free survival (RR 3.73, 95% CI 2.47-5.63). Circumferential pulmonary vein ablation significantly improved atrial tachyarrhythmia recurrence-free survival compared with antiarrhythmic drug therapy (75.7% vs 18.8%; RR 3.73, 95% CI 2.47-5.63).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: